Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression

He，Michelle Junyi1,2; Pu，Wenjun1,3; Wang，Xi4; Zhong，Xiaoni1; Zhao，Dong5; Zeng，Zhipeng1; Cai，Wanxia1; Liu，Jiayi1; Huang，Jianrong5; Tang，Donge1; Dai，Yong1,6

2022-12-01

10.1186/s12935-022-02775-9

Cancer Cell International   影响因子和分区

1475-2867

Background: Hepatocellular carcinoma (HCC) is one of the deadliest cancers and is mainly developed from chronic liver diseases such as hepatitis-B infection-associated liver cirrhosis (LC). The progression from LC to HCC makes the detection of diagnostic biomarkers to be challenging. Hence, there have been constant efforts to improve on identifying the critical and predictive changes accompanying the disease progression. Methods: In this study, we looked to using the mass spectrometry mediated spatial metabolomics technique to simultaneous examine hundreds of metabolites in an untargeted fashion. Additionally, metabolic profiles were compared between six subregions within the HCC tissue to collect spatial information. Results: Through those metabolites, altered metabolic pathways in LC and HCC were identified. Specifically, the amino acid metabolisms and the glycerophospholipid metabolisms experienced the most changes. Many of the altered metabolites and metabolic pathways were able to be connected through the urea cycle. Conclusions: The identification of the key metabolites and pathways can expand our knowledge on HCC metabolic reprogramming and help us exam potential biomarkers for earlier detection of the malignant disease progression.

Amino acid metabolism Disease progression Hepatocellular carcinoma Liver cirrhosis Spatial metabolomics

SCI

英语

通讯

Scientific Research Youth Fund of Shenzhen Third People's Hospital[G2021008] ; Guangxi Key Laboratory of Metabolic Diseases Research[20-06576] ; Shenzhen Science and Technology RD Fund[JCYJ20190809165813331] ; Shenzhen Key Medical Discipline Construction Fund[SZXK059]

Oncology

Oncology

WOS:000886967200002

BMC

2-s2.0-85142455835

Scopus

1.Clinical Medical Research Center,The Second Clinical Medical College of Jinan University,Shenzhen People’s Hospital,Shenzhen,No. 1017 Dongmen North Road,518020,China
2.Department of Biology,Department of Brain and Cognitive Sciences,Massachusetts Institute of Technology,Cambridge,02139,United States
3.The First Affiliated Hospital,Jinan University,Guangzhou,510632,China
4.The First Affiliated Hospital (Shenzhen People’s Hospital),Southern University of Science and Technology,Shenzhen,518055,China
5.Department of Nephrology Center,Department of Liver Transplant Center,The Third People’s Hospital of Shenzhen,The Second Affiliated Hospital of Southern University of Science and Technology,Shenzhen,Guangdong,518100,China
6.Guangxi Key Laboratory of Metabolic Disease Research,Central Laboratory of Guilin,924St Hospital,Guilin,541002,China

He，Michelle Junyi,Pu，Wenjun,Wang，Xi,et al. Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression[J]. Cancer Cell International,2022,22(1).

He，Michelle Junyi.,Pu，Wenjun.,Wang，Xi.,Zhong，Xiaoni.,Zhao，Dong.,...&Dai，Yong.(2022).Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression.Cancer Cell International,22(1).

He，Michelle Junyi,et al."Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression".Cancer Cell International 22.1(2022).